Taranabant

From Wikipedia, the free encyclopedia

Taranabant
Systematic (IUPAC) name
N-[(1S,2S)-3-(4-Chlorophenyl)-2-

(3-cyanophenyl)-1-methylpropyl]-2-methyl-2- ((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide
Identifiers
CAS number 701977-09-5
ATC code A08AX
PubChem  ?
Chemical data
Formula C27H25ClF3N3O2 
Mol. mass 515.95
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?
Legal status
Routes Oral

Taranabant (codenamed MK-0364) is a cannabinoid receptor type 1 inverse agonist being investigated as a potential treatment for obesity due to its anorectic effects.[1][2] It was discovered by Merck & Co.

As of March 2008, it is currently undergoing Phase III clinical studies.[3]

[edit] References

  1. ^ Armstrong HE, Galka A, Lin LS, Lanza TJ Jr, Jewell JP, Shah SK, et al. "Substituted acyclic sulfonamides as human cannabinoid-1 receptor inverse agonists." Bioorganic & Medicinal Chemistry Letters. 2007 Apr 15;17(8):2184-7. PMID 17293109. doi:10.1016/j.bmcl.2007.01.087
  2. ^ Fong TM, Guan XM, Marsh DJ, Shen CP, Stribling DS, Rosko KM, et al. "Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents." Journal of Pharmacology and Experimental Therapeutics. 2007 Jun;321(3):1013-22. PMID 17327489. doi:10.1124/jpet.106.118737
  3. ^ Merck & Co., Inc. product pipeline. Retrieved on 2008-03-28.
Tablets  This pharmacology-related article is a stub. You can help Wikipedia by expanding it.
v • d • e
Antiobesity preparations (A08)
Centrally acting
Peripherally acting
v • d • e
Cannabinoids
Plant cannabinoids
CBD • CBDV • CBN • CBG • CBV • CBL • THC • THC-C4 • THCV
Cannabinoid metabolites
Endogenous cannabinoids
Arachidonoyl ethanolamide (Anandamide or AEA) • 2-Arachidonoylglycerol (2-AG) • 2-Arachidonyl glyceryl ether (noladin ether) • Virodhamine • N-arachidonoyl-dopamine (NADA)
Synthetic cannabinoid agonists
Classical cannabinoids (Dibenzopyrans)

A-41988 • Ajulemic acid • AM-087 • AM-411 • AM-855 • AM-905 • AM-906 • AM-919 • AM-938 • AM-4030 • AMG-1 • AMG-3 • AMG-36 • AMG-41 • Dexanabinol (HU-211) • DMHP • Dronabinol • HU-210 • JWH-051 • JWH-133 • JWH-139 • L-759,633 • L-759,656 • Levonantradol • Nabilone • Nabitan • O-806 • O-823 • O-1057 • O-1125 • O-1238 • O-2545 • O-2694 • Parahexyl • THC-O-acetate • THC-O-phosphate
Nonclassical cannabinoids
Aminoalkylindoles

AM-630 • AM-1241 • JWH-015 • JWH-018 • JWH-073 • JWH-081 • JWH-200 • L-768,242 • Pravadoline • WIN 55,212-2
Aminoalkylpyrroles

JWH-030 • JWH-147 • JWH-307
Eicosanoids

AM-883 • Arachidonyl-2'-chloroethylamide • Arachidonylcyclopropylamide • Methanandamide • O-585 • O-689 • O-1812 • O-1860 • O-1861
Others

BAY 38-7271 • BAY 59-3074 • JWH-171 • O-2220
Endocannabinoid activity enhancers

AM-404 • N-arachidonoyl-serotonin • O-1624 • URB-597 • URB-754
Cannabinoid antagonists and inverse agonists

AM-251 • AM-281 • AM-630 • BML-190 • JTE-907 • LY-320,135 • NESS-0327 • O-1184 • O-2050 • O-2654 • Rimonabant • SLV-319 • SR-144,528 • Surinabant • Taranabant • VCHSR